Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IOBT NASDAQ:LIAN NASDAQ:MBRX NASDAQ:PHIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIOBTIO Biotech$0.05$0.14$0.03▼$2.79$3.45M0.887.09 million shsN/ALIANLianBio$0.14$0.13$0.27▼$4.99$34.47M0.231.04 million shs44 shsMBRXMoleculin Biotech$2.51+0.7%$2.35$1.79▼$28.61$13.31M1.74154,556 shs492,200 shsPHIOPhio Pharmaceuticals$1.11-3.1%$1.21$0.81▼$4.19$12.84M0.842.70 million shs68,459 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIOBTIO Biotech0.00%0.00%-7.51%-86.29%-95.13%LIANLianBio0.00%+14.75%+12.00%+50.38%-26.99%MBRXMoleculin Biotech+0.40%-2.73%+3.32%-42.23%-90.07%PHIOPhio Pharmaceuticals-0.87%-6.56%-8.06%+23.90%-43.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIOBTIO Biotech$0.05$0.14$0.03▼$2.79$3.45M0.887.09 million shsN/ALIANLianBio$0.14$0.13$0.27▼$4.99$34.47M0.231.04 million shs44 shsMBRXMoleculin Biotech$2.51+0.7%$2.35$1.79▼$28.61$13.31M1.74154,556 shs492,200 shsPHIOPhio Pharmaceuticals$1.11-3.1%$1.21$0.81▼$4.19$12.84M0.842.70 million shs68,459 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIOBTIO Biotech0.00%0.00%-7.51%-86.29%-95.13%LIANLianBio0.00%+14.75%+12.00%+50.38%-26.99%MBRXMoleculin Biotech+0.40%-2.73%+3.32%-42.23%-90.07%PHIOPhio Pharmaceuticals-0.87%-6.56%-8.06%+23.90%-43.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIOBTIO Biotech 1.60Reduce$3.507,191.67% UpsideLIANLianBio 0.00N/AN/AN/AMBRXMoleculin Biotech 2.33Hold$22.00777.19% UpsidePHIOPhio Pharmaceuticals 2.00Hold$14.001,166.97% UpsideCurrent Analyst Ratings BreakdownLatest IOBT, PHIO, MBRX, and LIAN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026MBRXMoleculin Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026PHIOPhio Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026IOBTIO Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/24/2026MBRXMoleculin Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.002/10/2026PHIOPhio Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIOBTIO BiotechN/AN/AN/AN/A$0.71 per shareN/ALIANLianBioN/AN/AN/AN/A$2.71 per shareN/AMBRXMoleculin BiotechN/AN/AN/AN/A$4.69 per shareN/APHIOPhio PharmaceuticalsN/AN/AN/AN/A$1.87 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIOBTIO Biotech-$95.49M-$1.35N/AN/AN/AN/A-517.22%-200.69%5/13/2026 (Estimated)LIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/AMBRXMoleculin Biotech-$33.56M-$32.75N/AN/AN/AN/AN/A-60.88%5/11/2026 (Estimated)PHIOPhio Pharmaceuticals-$8.70M-$1.45N/AN/AN/AN/A-66.59%-60.26%5/21/2026 (Estimated)Latest IOBT, PHIO, MBRX, and LIAN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026PHIOPhio Pharmaceuticals-$0.24N/AN/AN/AN/AN/A5/13/2026Q4 2025IOBTIO Biotech-$0.10N/AN/AN/AN/AN/A5/11/2026Q1 2026MBRXMoleculin Biotech-$1.69N/AN/AN/AN/AN/A5/7/2026Q1 2026PHIOPhio PharmaceuticalsN/A-$0.34N/A-$0.34N/AN/A3/5/2026Q4 2025PHIOPhio Pharmaceuticals-$0.34-$0.15+$0.19-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIOBTIO BiotechN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIOBTIO Biotech18.292.012.01LIANLianBioN/A10.0610.06MBRXMoleculin BiotechN/A1.411.41PHIOPhio PharmaceuticalsN/A16.0316.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIOBTIO Biotech54.76%LIANLianBio74.85%MBRXMoleculin Biotech15.52%PHIOPhio Pharmaceuticals57.31%Insider OwnershipCompanyInsider OwnershipIOBTIO Biotech2.30%LIANLianBio7.59%MBRXMoleculin Biotech1.10%PHIOPhio Pharmaceuticals0.89%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIOBTIO Biotech3071.95 million68.50 millionNot OptionableLIANLianBio110108.06 million99.86 millionNot OptionableMBRXMoleculin Biotech205.34 million5.28 millionNot OptionablePHIOPhio Pharmaceuticals1011.62 million11.51 millionNot OptionableIOBT, PHIO, MBRX, and LIAN HeadlinesRecent News About These CompaniesPhio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business UpdateMay 7 at 4:05 PM | newsfilecorp.comNPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15 ...April 14, 2026 | finanznachrichten.dePhio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026April 13, 2026 | newsfilecorp.comNPhio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026April 9, 2026 | finance.yahoo.comPyramid Pharma Services Announces Drug Product Manufacturing Agreement for Phio Pharmaceuticals’ Lead Oncology CandidateApril 8, 2026 | jsonline.comJPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762March 31, 2026 | finanznachrichten.dePhio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762March 30, 2026 | newsfilecorp.comNPhio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring ...March 23, 2026 | finance.yahoo.comPhio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline AdvancementMarch 23, 2026 | newsfilecorp.comNPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family OfficeMarch 16, 2026 | finanznachrichten.dePhio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family OfficeMarch 16, 2026 | newsfilecorp.comNB2i Digital Highlights Life Sciences Virtual Investor Forum as a Featured ConferenceMarch 11, 2026 | finance.yahoo.comPhio Pharmaceuticals Corp.: Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDTMarch 10, 2026 | finanznachrichten.dePhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTMarch 10, 2026 | financialpost.comFPhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTMarch 10, 2026 | globenewswire.comPhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTMarch 10, 2026 | financialpost.comFPhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTMarch 10, 2026 | globenewswire.comPhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDTMarch 10, 2026 | newsfilecorp.comNPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business UpdateMarch 5, 2026 | finanznachrichten.dePhio Pharmaceuticals Reports 2025 Year-End Financial Results and Business UpdateMarch 5, 2026 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIOBT, PHIO, MBRX, and LIAN Company DescriptionsIO Biotech NASDAQ:IOBT$0.05 0.00 (0.00%) As of 04/7/2026IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.LianBio NASDAQ:LIAN$0.14 0.00 (0.00%) As of 05/6/2026LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.Moleculin Biotech NASDAQ:MBRX$2.51 +0.02 (+0.72%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.Phio Pharmaceuticals NASDAQ:PHIO$1.10 -0.04 (-3.07%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
